aTyr Pharma Phase 3 EFZO-FIT topline due mid-Sept; Q2 cash $83.2M, raised $30.7M ATM

aTYR PHARMA INC

Completed last patient visit in Phase 3 EFZO-FIT study for pulmonary sarcoidosis; topline results expected mid-September 2025.
Interim Phase 2 data in SSc-ILD showed stable/improved mRSS in diffuse patients; no treatment-related serious adverse events.
ATYR0101 advanced to IND candidate for pulmonary fibrosis; IND filing planned in H2 2026.
Cash, equivalents and investments $83.2M at June 30, 2025; raised ~$30.7M in ATM offering after quarter-end.
R&D expenses $15.4M, G&A $4.9M for Q2 2025; cash runway sufficient for one year after Phase 3 readout.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.